AUTHOR=Frederiksen Kristian Steen , Jensen Camilla Steen , Høgh Peter , Gergelyffy Robert , Waldemar Gunhild , Andersen Birgitte Bo , Gottrup Hanne , Vestergaard Karsten , Wermuth Lene , Søndergaard Helle Bach , Sellebjerg Finn , Hasselbalch Steen Gregers , Simonsen Anja Hviid 

TITLE=Aerobic exercise does not affect serum neurofilament light in patients with mild Alzheimer’s disease

JOURNAL=Frontiers in Neuroscience

VOLUME=17

YEAR=2023

URL=https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1108191

DOI=10.3389/fnins.2023.1108191

ISSN=1662-453X

ABSTRACT=<sec><title>Introduction</title><p>Aerobic exercise has been shown to modify Alzheimer pathology in animal models, and in patients with multiple sclerosis to reduce neurofilament light (NfL), a biomarker of neurodegeneration.</p></sec><sec><title>Objective</title><p>To investigate whether a 16-week aerobic exercise program was able to reduce serum NfL in patients with mild Alzheimer’s disease (AD).</p></sec><sec><title>Methods</title><p>This is a secondary analysis of data from the multi-center Preserving Cognition, Quality of Life, Physical Health, and Functional Ability in Alzheimer’s disease: The Effect of Physical Exercise (ADEX) study. Participants were randomized to 16 weeks of moderate intensity aerobic exercise or usual care. Clinical assessment and measurement of serum NfL was done at baseline and after the intervention.</p></sec><sec><title>Results</title><p>A total of 136 participants were included in the analysis. Groups were comparable at baseline except for <italic>APOE</italic>ε<italic>4</italic> carriership which was higher in the usual care group (75.3 versus 60.2%; <italic>p</italic> = 0.04). There was no effect of the intervention on serum NfL [intervention: baseline NfL (pg/mL) 25.76, change from baseline 0.87; usual care: baseline 27.09, change from baseline −1.16, <italic>p</italic> = 0.09].</p></sec><sec><title>Conclusion</title><p>The findings do not support an effect of the exercise intervention on a single measure of neurodegeneration in AD. Further studies are needed using other types and durations of exercise and other measures of neurodegeneration.</p></sec><sec><title>Clinical trial registration</title><p><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">clinicaltrials.gov</ext-link>, identifier NCT01681602.</p></sec>